Eur Urol Oncol: Comparison of the detection of clinically significant prostate cancer with a four-core targeted biopsy versus a nine-core targeted saturation biopsy for transperineal prostate fusion biopsy

Multiparametric magnetic resonance imaging (mpMRI) and targeted biopsy (TB) help accurately detect clinically significant prostate cancer (csPC

Recently, researchers from Germany published an article in Eur Urol Oncol evaluating the csPC detection rate of two targeted MRI/transrectal ultrasonography (TRUS) fusion biopsy methods, namely conventional TB and targeted saturation biopsy (TS).

The study was a prospective single-center design in which 170 men were biopsy

The researchers used the McNemar test to analyze PC and csPC (International Society of Urological Pathology Grade ≥2) detection rates for systemic biopsy (SB), TB, and TS, and compared

The results of the study showed that 57 men in the TS group were diagnosed with csPC and 36 men in the TB group were diagnosed with csPC

Comparison of detection rates for different methods

In summary, there was no significant difference

Original Source:

Yasemin Melisa Saner ， Manuel Wiesenfarth ， Vivienn Weru et al.